IP Library › Granted Patent US 12,588,675
Granted Patent B2
US 12,588,675 · App. 18/130,042 · Granted Mar 31, 2026

Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms

Inventors: Aleksa Jovanovic (Fort Worth, TX); Lei Shi (Mansfield, TX); Eric Roche (Fort Worth, TX); Paul Renick (Fort Worth, TX)
Assignee: SMITH & NEPHEW, INC.
A01N37/02A01N25/04A01N25/30A01N37/46A01N59/12A01N59/16A61K9/0014A61K9/06A61K31/23A61K31/25A61K31/625A61K31/7036A61K31/79A61K33/18A61K33/38A61K38/12A61K45/06A61K47/10A61K47/14A61K47/26A61K47/38A61L26/0066A61L27/025A61L27/047A61L27/306A61L27/34A61L27/52A61L27/54A61L29/02A61L29/085A61L29/106A61L29/145A61L29/16A61L31/022A61L31/028A61L31/088A61L31/10A61L31/145A61L31/16A61P31/04A61L2300/404A61L2300/406A61L2420/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,588,675
App. No.
18/130,042
Granted
Mar 31, 2026
Kind
B2
Abstract

The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.

Claims (31)

1 . A method of treating a wound, mucous membrane lesion, or skin lesion; wherein the wound, mucous membrane lesion and skin lesion is infected or contaminated with a bacterial biofilm, the method comprising topically administering to the wound, mucous membrane lesion, or skin lesion a composition comprising a combination of a pharmaceutical carrier and an antibacterial agent,

wherein the pharmaceutical carrier is not an emulsion,

wherein the composition does not include a silver compound, an organic acid, and a chelating agent,

wherein the antibacterial agent comprises at least one medium polarity oil having an octanol-water partition coefficient (log P) of 0.5 to 2.0 and at least one iodine compound,

wherein the at least one medium polarity oil is benzyl alcohol or propyl gallate and is present at a concentration of 8% w/w to 12% w/w,

wherein the at least one iodine compound is:

povidone-iodine present at a concentration of about 5% w/w; or

cadexomer-iodine is present at a concentration of 45% w/w to 55% w/w, and

wherein the combination of the at least one medium polarity oil and the at least one iodine compound exhibits synergistic antibacterial activity against the biofilm.

2 . The method of claim 1 , wherein the pharmaceutical carrier is suitable for topical treatment and is a solution, suspension, liquid, gel, ringing gel, ointment, paste, aerosol spray, aerosol foam, non-aerosol spray, non-aerosol foam, film, or sheet.

3 . The method of claim 1 , wherein the at least one medium polarity oil is present at a concentration of 9% w/w to 11% w/w.

4 . The method of claim 1 , wherein the bacterial biofilm is a gram-positive or a gram-negative bacterial biofilm.

5 . The method of claim 4 , wherein the gram-positive bacterial biofilm is a Staphylococcus sp, and wherein the gram-negative bacterial biofilm is a Pseudomonas sp.

6 . The method of claim 1 , wherein:

the wound is a chronic wound, and the chronic wound is a diabetic foot ulcer, venous ulcer, arterial ulcer, decubitus ulcer, stasis ulcer, pressure ulcer, or burn; or

the skin lesion or mucous membrane lesion is a blister, ulceration, abrasion, wart, scrape, or infection.

7 . A method of reducing bacteria in or eliminating a bacterial biofilm on a biological surface, the method comprising administering to the biological surface a composition comprising a combination of a pharmaceutical carrier and an antibacterial agent,

wherein the pharmaceutical carrier is not an emulsion,

wherein the composition does not include a silver compound, an organic acid, and a chelating agent,

wherein the antibacterial agent comprises at least one medium polarity oil having an octanol-water partition coefficient (log P) of 0.5 to 2.0 and at least one iodine compound,

wherein the at least one medium polarity oil is benzyl alcohol or propyl gallate and is present at a concentration of 8% w/w to 12% w/w,

wherein the at least one iodine compound is:

povidone-iodine and is present at a concentration of about 5% w/w; or

cadexomer-iodine is present at a concentration of 45% w/w to 55% w/w, and

wherein the combination of the at least one medium polarity oil and the at least one iodine compound exhibits synergistic antibacterial activity against the biofilm.

8 . The method of claim 7 , wherein the pharmaceutical carrier is suitable for application to a biological surface and is a lotion, solution, suspension, liquid, emulsion, cream, gel, ringing gel, ointment, paste, aerosol spray, aerosol foam, non-aerosol spray, non-aerosol foam, film, or sheet.

9 . The method of claim 7 , wherein the bacterial biofilm is a Staphylococcus sp. biofilm or a Pseudomonas sp. biofilm.

10 . The method of claim 7 , wherein the biological surface is:

a chronic wound, and the chronic wound is a diabetic foot ulcer, venous ulcer, arterial ulcer, decubitus ulcer, stasis ulcer, pressure ulcer, or burn; or

a skin lesion or mucous membrane lesion, and the skin lesion or mucous membrane lesion is a blister, ulceration, abrasion, wart, scrape, or infection.

11 . The method of claim 7 , wherein the at least one medium polarity oil is present at a concentration of 9% w/w to 11% w/w.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2023
From: JOVANOVIC, ALEKSA; SHI, LEI; ROCHE, ERIC; RENICK, PAUL
To: SMITH & NEPHEW, INC.
Reel/Frame 063203/0694 →
Continuity (5)
Continuation 17545409 · Dec 8, 2021
Continuation 16529303 · Aug 1, 2019
Continuation 15754703
Provisional Application 62209181 · Aug 24, 2015
Related Publication 20230345938A1 · Nov 2, 2023
References Cited (55)
US 5217493A · Raad et al. · 1993 [cited by applicant]
US 6399092B1 · Hobson et al. · 2002 [cited by applicant]
US 20090155215A1 · Collins et al. · 2009 [cited by applicant]
US 20090263439A1 · Casas-Sanchez et al. · 2009 [cited by applicant]
US 20090312279A1 · Mookerjee et al. · 2009 [cited by applicant]
US 20100203139A1 · Baker et al. · 2010 [cited by applicant]
US 20120201902A1 · Modak et al. · 2012 [cited by applicant]
US 20130085103A1 · Mohan et al. · 2013 [cited by applicant]
US 20160015047A1 · Gawande et al. · 2016 [cited by applicant]
CA 2656332A1 · 2008 [cited by examiner]
CN 1045701 · 1990 [cited by applicant]
CN 1209065 · 1999 [cited by applicant]
CN 1292641 · 2001 [cited by applicant]
CN 1294519 · 2001 [cited by applicant]
CN 1327382 · 2001 [cited by applicant]
CN 1572301 · 2005 [cited by applicant]
CN 1600300 · 2005 [cited by applicant]
CN 1744905 · 2006 [cited by applicant]
CN 101919807 · 2010 [cited by applicant]
CN 102210648 · 2011 [cited by applicant]
CN 102223876 · 2011 [cited by applicant]
CN 102939097 · 2013 [cited by applicant]
CN 103720640 · 2014 [cited by applicant]
CN 104302359 · 2015 [cited by applicant]
CN 104586888 · 2015 [cited by applicant]
CN 104644667 · 2015 [cited by applicant]
JP 2012056854 · 2012 [cited by applicant]
JP 2013245187 · 2013 [cited by applicant]
WO WO2004052308 · 2004 [cited by applicant]
WO WO2011002929 · 2011 [cited by applicant]
WO WO2011035158 · 2011 [cited by applicant]
WO WO2011089379A2 · 2011 [cited by examiner]
WO WO2014201541 · 2014 [cited by applicant]
Goldenheim, In vitro efficacy of povidone-iodine solution and cream against methicillin-resistant [cited by examiner]
Thorn et al., In vitro comparison of antimicrobial activity of iodine and silver dressings against biofilms, Journal of Wound Care vol. 18 , No. 8 , Aug. 2009 (Year: 2009). [cited by examiner]
A Versatile In Vitro Biofilm Model Using Two Wound Pathogens to Screen Formulations, 2010 Wound Healing Society Annual Meeting, Poster Abstract BRC09, Apr. 18, 2010, Orlando, FL. [cited by applicant]
“Research on Microbial Biofilms,” National Institutes of Health, PA No. PA-03-047, Dec. 20, 2002. Accessed on Aug. 25, 2018 on internet at https://grants.nih.gov/grants/pa-files/pa-03-047.html. [cited by applicant]
Akiyama et al., “Assessment of Cadexomer lodine against [cited by applicant]
Attinger et al., “Clinically Addressing Biofilm in Chronic Wounds” [cited by applicant]
Bjarnsholt, “Why Chronic Wounds Will Not Heal: A Novel Hypothesis,” Wound Repair and Regeneration, 2008. [cited by applicant]
Borriello, et al., “Oxygen Limitation Contributes to Antibiotic Tolerance of Pseudomonas Aeruginosa in Biofilms,” Antimicrobial Agents and Chemotherapy, 48(7); 2659-2664, 2004. [cited by applicant]
Hess et al., “Antibacterial Synergy of Glycerol Monolaurate and Aminoglycosides in Staphylococcus aureus Biofilms” [cited by applicant]
International Search Report and Written Opinion Issued in Corresponding PCT Application No. PCT/us2016/048110, mailed Nov. 2, 2016. [cited by applicant]
Jacobsen, “Investigating the Humoral Immune Response in Chronic Venous Leg Ulcer Patients Colonised with Pseudomonas/Aeruginosa,” International Wound Journal, 20110. [cited by applicant]
Junka et al., “Efficacy of antiseptics containing povidone-iodine, octenidine dihydrochloride and ethacridine lactate against biofilm formed by Pseudomonas aeruginosa and [cited by applicant]
Matsumoto et al., “Duration of Absorption-Enhancing Effect of Sodium Octanoate, Sodium Hexanoate or Glyceryl-1-monooctanoate on Rectal Absorption of Gentamicin in Rabbits” [cited by applicant]
Merck, Page, “Description of Skin Lesions,” Merck Manual Professional Version, 2013 http://merckmanuals.com/professional/dermatologic-disorders/approach-to-the- dermatologic-patient/description-of-skin-lesions. [cited by applicant]
Mertz, “Cutaneous Biofilms: Friend or Foe?”, [cited by applicant]
Office Action issued in Corresponding Chinese Application No. 201680049463.4, dated Jun. 24, 2020 (English Translation provided). [cited by applicant]
Office Action issued in Corresponding Japanese Application No. 2018-510413, dated Jul. 20, 2020 (English Translation provided). [cited by applicant]
O'Meara et al., “Antibiotics and antiseptics for venous leg ulcers” [cited by applicant]
Research Council Meeting Abstract of Japan Society of Plastic and Reconstructive Surgery 2013, vol. 22, p. 85, O-2. [cited by applicant]
Sanchez, Jr. et al., “D-Amino Acids Enhance the Activity of Antimicrobials against Biofilms of Clinical Wound Isolates of [cited by applicant]
Williamson, et al., “Heterogeneity in Pseudomonas Aeroginosa Biofilms Includes Expression of Ribosome Hibernation Factors in the Antibiotic-Tolerant Subpopulation and Hypoxia-Induced Stress Response in the Metabolically… [cited by applicant]
Zheng, et al., “Penetration of Rifampin Through [cited by applicant]